000 01662 a2200481 4500
005 20250515185120.0
264 0 _c20100105
008 201001s 0 0 eng d
022 _a1464-3405
024 7 _a10.1016/j.bmcl.2009.08.080
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMowbray, Charles E
245 0 0 _aPyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
_h[electronic resource]
260 _bBioorganic & medicinal chemistry letters
_cOct 2009
300 _a5857-60 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAcquired Immunodeficiency Syndrome
_xdrug therapy
650 0 4 _aAnimals
650 0 4 _aAnti-HIV Agents
_xchemical synthesis
650 0 4 _aCell Line
650 0 4 _aDrug Resistance, Viral
650 0 4 _aHIV Reverse Transcriptase
_xantagonists & inhibitors
650 0 4 _aHumans
650 0 4 _aMicrosomes, Liver
_xmetabolism
650 0 4 _aNitriles
_xchemical synthesis
650 0 4 _aPyrazoles
_xchemical synthesis
650 0 4 _aRats
650 0 4 _aReverse Transcriptase Inhibitors
_xchemical synthesis
700 1 _aBurt, Catherine
700 1 _aCorbau, Romuald
700 1 _aGayton, Simon
700 1 _aHawes, Michael
700 1 _aPerros, Manos
700 1 _aTran, Isabelle
700 1 _aPrice, David A
700 1 _aQuinton, Faye J
700 1 _aSelby, Matthew D
700 1 _aStupple, Paul A
700 1 _aWebster, Rob
700 1 _aWood, Anthony
773 0 _tBioorganic & medicinal chemistry letters
_gvol. 19
_gno. 20
_gp. 5857-60
856 4 0 _uhttps://doi.org/10.1016/j.bmcl.2009.08.080
_zAvailable from publisher's website
999 _c19147035
_d19147035